MacroGenics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.94
- Today's High:
- $5.47
- Open Price:
- $5.42
- 52W Low:
- $2.935
- 52W High:
- $7.9
- Prev. Close:
- $5.42
- Volume:
- 556104
Company Statistics
- Market Cap.:
- $335.77 million
- Book Value:
- 2.77
- Revenue TTM:
- $152.46 million
- Operating Margin TTM:
- -63.2%
- Gross Profit TTM:
- $-62469000
- Profit Margin:
- 4.89%
- Return on Assets TTM:
- -23%
- Return on Equity TTM:
- 4.74%
Company Profile
MacroGenics Inc had its IPO on 2013-10-10 under the ticker symbol MGNX.
The company operates in the Healthcare sector and Biotechnology industry. MacroGenics Inc has a staff strength of 357 employees.
Stock update
Shares of MacroGenics Inc opened at $5.42 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.94 - $5.47, and closed at $4.94.
This is a -8.86% slip from the previous day's closing price.
A total volume of 556,104 shares were traded at the close of the day’s session.
In the last one week, shares of MacroGenics Inc have increased by +1.65%.
MacroGenics Inc's Key Ratios
MacroGenics Inc has a market cap of $335.77 million, indicating a price to book ratio of 3.1198 and a price to sales ratio of 4.079.
In the last 12-months MacroGenics Inc’s revenue was $152.46 million with a gross profit of $-62469000 and an EBITDA of $-84490000. The EBITDA ratio measures MacroGenics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, MacroGenics Inc’s operating margin was -63.2% while its return on assets stood at -23% with a return of equity of 4.74%.
In Q2, MacroGenics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 49.5%.
MacroGenics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 45.1667
- PEG
- 0.01
Its diluted EPS in the last 12-months stands at $0.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.01. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MacroGenics Inc’s profitability.
MacroGenics Inc stock is trading at a EV to sales ratio of 3.0927 and a EV to EBITDA ratio of -1.5663. Its price to sales ratio in the trailing 12-months stood at 4.079.
MacroGenics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $305.65 million
- Total Liabilities
- $68.21 million
- Operating Cash Flow
- $-113476000.00
- Capital Expenditure
- $286000
- Dividend Payout Ratio
- 0%
MacroGenics Inc ended 2024 with $305.65 million in total assets and $0 in total liabilities. Its intangible assets were valued at $305.65 million while shareholder equity stood at $171.54 million.
MacroGenics Inc ended 2024 with $0 in deferred long-term liabilities, $68.21 million in other current liabilities, 619000.00 in common stock, $-1074234000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $108.76 million and cash and short-term investments were $240.35 million. The company’s total short-term debt was $4,161,000 while long-term debt stood at $0.
MacroGenics Inc’s total current assets stands at $240.35 million while long-term investments were $0 and short-term investments were $131.59 million. Its net receivables were $6.41 million compared to accounts payable of $3.80 million and inventory worth $1.44 million.
In 2024, MacroGenics Inc's operating cash flow was $-113476000.00 while its capital expenditure stood at $286000.
Comparatively, MacroGenics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $4.94
- 52-Week High
- $7.9
- 52-Week Low
- $2.935
- Analyst Target Price
- $12.38
MacroGenics Inc stock is currently trading at $4.94 per share. It touched a 52-week high of $7.9 and a 52-week low of $7.9. Analysts tracking the stock have a 12-month average target price of $12.38.
Its 50-day moving average was $5.06 and 200-day moving average was $5.86 The short ratio stood at 7.78 indicating a short percent outstanding of 0%.
Around 268.7% of the company’s stock are held by insiders while 9463.8% are held by institutions.
Frequently Asked Questions About MacroGenics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.